Forte contends that cell therapy can potentially address unmet medical needs in orthopedics such as incomplete fracture healing, which affects hundreds of thousands of patients worldwide. Bone Therapeutics remains on target for delivery of topline results in early 2023 for its Phase IIB study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures.
"A complicated tibial fracture that doesn't heal costs upwards of $30,000," Forte said. "If we're able to transform a complicated fracture into an uncomplicated fracture by using these cells to accelerate the regeneration, we're making $20,000 [in] savings."
Watch the video below to learn more.